| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
|
J Clin Oncol
|
2003
|
15.10
|
|
2
|
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
|
Lancet
|
2008
|
10.74
|
|
3
|
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
|
J Clin Oncol
|
2008
|
7.35
|
|
4
|
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
|
J Clin Oncol
|
2006
|
6.95
|
|
5
|
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2011
|
2.92
|
|
6
|
Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.
|
Lancet
|
2002
|
2.78
|
|
7
|
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.
|
N Engl J Med
|
2013
|
2.38
|
|
8
|
A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).
|
Eur J Cancer
|
2013
|
2.14
|
|
9
|
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.
|
J Natl Cancer Inst
|
2007
|
2.11
|
|
10
|
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.
|
J Clin Oncol
|
2004
|
2.05
|
|
11
|
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
|
J Clin Oncol
|
2008
|
1.97
|
|
12
|
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
|
J Clin Oncol
|
2012
|
1.97
|
|
13
|
Potential regional differences for the tolerability profiles of fluoropyrimidines.
|
J Clin Oncol
|
2008
|
1.92
|
|
14
|
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.
|
J Clin Oncol
|
2013
|
1.66
|
|
15
|
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
|
J Clin Oncol
|
2008
|
1.65
|
|
16
|
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.
|
Invest New Drugs
|
2010
|
1.62
|
|
17
|
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
|
Int J Cancer
|
2011
|
1.51
|
|
18
|
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
|
Clin Cancer Res
|
2011
|
1.39
|
|
19
|
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).
|
J Clin Oncol
|
2003
|
1.30
|
|
20
|
Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.
|
Lung Cancer
|
2009
|
1.24
|
|
21
|
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2009
|
1.24
|
|
22
|
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
|
Clin Colorectal Cancer
|
2011
|
1.16
|
|
23
|
[Standards, Options and Recommendations for the management of non-small cell lung carcinoma patients].
|
Bull Cancer
|
2003
|
1.14
|
|
24
|
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials.
|
BMJ Open
|
2013
|
1.07
|
|
25
|
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.
|
J Clin Oncol
|
2006
|
1.06
|
|
26
|
Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.
|
J Clin Oncol
|
2010
|
1.03
|
|
27
|
Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome.
|
J Thorac Oncol
|
2011
|
1.02
|
|
28
|
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer.
|
Cochrane Database Syst Rev
|
2015
|
0.96
|
|
29
|
RAS mutations in colorectal cancer.
|
N Engl J Med
|
2013
|
0.96
|
|
30
|
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
|
J Clin Oncol
|
2005
|
0.96
|
|
31
|
Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.
|
Oncologist
|
2010
|
0.96
|
|
32
|
Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients.
|
Lung Cancer
|
2013
|
0.93
|
|
33
|
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial.
|
Lung Cancer
|
2009
|
0.92
|
|
34
|
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
|
J Transl Med
|
2011
|
0.91
|
|
35
|
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.
|
Br J Clin Pharmacol
|
2012
|
0.90
|
|
36
|
The role of UFT in metastatic colorectal cancer.
|
Oncology
|
2009
|
0.88
|
|
37
|
Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivo.
|
Cancer Res
|
2012
|
0.86
|
|
38
|
Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie.
|
World J Urol
|
2005
|
0.86
|
|
39
|
A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
|
Clin Pharmacokinet
|
2007
|
0.84
|
|
40
|
Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.
|
J Thorac Oncol
|
2015
|
0.84
|
|
41
|
Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.
|
Lung Cancer
|
2011
|
0.84
|
|
42
|
A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics.
|
Clin Lung Cancer
|
2013
|
0.83
|
|
43
|
Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma.
|
Clin Colorectal Cancer
|
2011
|
0.83
|
|
44
|
Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status.
|
Drugs
|
2015
|
0.83
|
|
45
|
Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
|
Cancer
|
2002
|
0.79
|
|
46
|
Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2010
|
0.79
|
|
47
|
Focus on the controversial activation of human iNKT cells by 4-deoxy analogue of KRN7000.
|
J Med Chem
|
2009
|
0.78
|
|
48
|
Adjuvant chemotherapy for non-small-cell lung cancer: it does not always fade with time.
|
J Clin Oncol
|
2009
|
0.78
|
|
49
|
[Optimizing good use and costs of anticancer drugs: A French inter regional study of the Observatory of Cancer].
|
Bull Cancer
|
2013
|
0.77
|
|
50
|
3-fluoro- and 3,3-difluoro-3,4-dideoxy-KRN7000 analogues as new potent immunostimulator agents: total synthesis and biological evaluation in human invariant natural killer T cells and mice.
|
J Med Chem
|
2012
|
0.77
|
|
51
|
A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors.
|
Anticancer Drugs
|
2010
|
0.76
|
|
52
|
Microsatellite instability and mismatch repair genes in colorectal cancer: useful tools for managing patients and counseling their relatives.
|
Clin Colorectal Cancer
|
2010
|
0.75
|
|
53
|
Therapeutic strategies for colorectal cancer in Europe and the United States: focus on chemotherapy for advanced colorectal cancer.
|
Int J Clin Oncol
|
2002
|
0.75
|
|
54
|
[Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome].
|
Zhongguo Fei Ai Za Zhi
|
2013
|
0.75
|
|
55
|
[Radiation therapy with 131I-MIBG is still relevant for metastatic carcinoid tumors].
|
Gastroenterol Clin Biol
|
2005
|
0.75
|
|
56
|
Repeat hepatectomy for colorectal liver metastases.
|
Int Surg
|
2006
|
0.75
|
|
57
|
[2000 Standards, Options and Recommendations for prognostic value of oncogenes and tumor suppressor genes in non small cell lung cancer].
|
Bull Cancer
|
2002
|
0.75
|
|
58
|
Prospects for colorectal cancer treatment: oral chemotherapy and targeted biotherapy.
|
Expert Rev Anticancer Ther
|
2003
|
0.75
|
|
59
|
[Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group].
|
Prog Urol
|
2002
|
0.75
|